Valeo Financial Advisors’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $532K | Buy |
10,149
+532
| +6% | +$28.1K | 0.01% | 431 |
|
|
2026
Q1 | $531K | Sell |
9,617
-5,315
| -36% | -$288K | 0.01% | 397 |
|
|
2025
Q4 | $732K | Buy |
14,932
+854
| +6% | +$39.8K | 0.02% | 372 |
|
|
2025
Q3 | $608K | Buy |
14,078
+999
| +8% | +$39K | 0.01% | 419 |
|
|
2025
Q2 | $502K | Buy |
13,079
+478
| +4% | +$18.3K | 0.01% | 450 |
|
|
2025
Q1 | $488K | Buy |
12,601
+4,221
| +50% | +$155K | 0.01% | 419 |
|
|
2024
Q4 | $283K | Sell |
8,380
-3,907
| -32% | -$141K | 0.01% | 560 |
|
|
2024
Q3 | $502K | Sell |
12,287
-89
| -0.7% | -$3.64K | 0.01% | 408 |
|
|
2024
Q2 | $476K | Sell |
12,376
-1,953
| -14% | -$82.2K | 0.01% | 402 |
|
|
2024
Q1 | $585K | Buy |
14,329
+57
| +0.4% | +$2.35K | 0.02% | 330 |
|
|
2023
Q4 | $529K | Buy |
14,272
+713
| +5% | +$25.6K | 0.02% | 344 |
|
|
2023
Q3 | $492K | Sell |
13,559
-4,999
| -27% | -$177K | 0.02% | 336 |
|
|
2023
Q2 | $661K | Buy |
18,558
+886
| +5% | +$31.8K | 0.03% | 264 |
|
|
2023
Q1 | $629K | Buy |
17,672
+2,504
| +17% | +$87.6K | 0.03% | 286 |
|
|
2022
Q4 | $533K | Buy |
15,168
+4,220
| +39% | +$141K | 0.03% | 275 |
|
|
2022
Q3 | $322K | Sell |
10,948
-291
| -3% | -$11K | 0.02% | 327 |
|
|
2022
Q2 | $612K | Sell |
11,239
-2,117
| -16% | -$117K | 0.04% | 226 |
|
|
2022
Q1 | $727K | Sell |
13,356
-114
| -0.8% | -$6.19K | 0.04% | 251 |
|
|
2021
Q4 | $743K | Sell |
13,470
-2,508
| -16% | -$130K | 0.04% | 228 |
|
|
2021
Q3 | $763K | Buy |
15,978
+9,053
| +131% | +$455K | 0.04% | 223 |
|
|
2021
Q2 | $345K | Buy |
6,925
+491
| +8% | +$23.6K | 0.02% | 335 |
|
|
2021
Q1 | $287K | Sell |
6,434
-400
| -6% | -$18.2K | 0.01% | 366 |
|
|
2020
Q4 | $314K | Buy |
6,834
+1,979
| +41% | +$90.9K | 0.02% | 324 |
|
|
2020
Q3 | $228K | Sell |
4,855
-4,617
| -49% | -$231K | 0.02% | 300 |
|
|
2020
Q2 | $483K | Buy |
9,472
+1,360
| +17% | +$69.8K | 0.04% | 189 |
|
|
2020
Q1 | $391K | Sell |
8,112
-129
| -2% | -$6.88K | 0.04% | 198 |
|
|
2019
Q4 | $484K | Buy |
8,241
+785
| +11% | +$43.7K | 0.05% | 193 |
|
|
2019
Q3 | $398K | Sell |
7,456
-215
| -3% | -$11.1K | 0.04% | 196 |
|
|
2019
Q2 | $384K | Sell |
7,671
-2,335
| -23% | -$117K | 0.04% | 200 |
|
|
2019
Q1 | $523K | Sell |
10,006
-19,439
| -66% | -$971K | 0.06% | 172 |
|
|
2018
Q4 | $1.41M | Sell |
29,445
-1,302
| -4% | -$64.1K | 0.2% | 86 |
|
|
2018
Q3 | $1.5M | Buy |
30,747
+1,096
| +4% | +$55.7K | 0.2% | 82 |
|
|
2018
Q2 | $1.47M | Buy |
29,651
+36
| +0.1% | +$1.81K | 0.21% | 82 |
|
|
2018
Q1 | $1.45M | Buy |
29,615
+21,612
| +270% | +$1.01M | 0.23% | 75 |
|
|
2017
Q4 | $355K | Buy |
8,003
+1,018
| +15% | +$47K | 0.06% | 182 |
|
|
2017
Q3 | $354K | Buy |
+6,985
| New | +$354K | 0.08% | 157 |
|
Other funds holding GSK
JEST
Valeo Financial Advisors's GSK Position: Q2 2026 in Review
Valeo Financial Advisors increased its GSK (GSK) stake by 5.5% in Q2 2026, buying an estimated $28.1K and bringing the position to 10,149 shares worth $532K. The position accounts for 0.01% of the portfolio, ranked #431.
Valeo Financial Advisors first reported a position in GSK in Q3 2017 and has held it in 36 quarters since. The position peaked at $1.5M in Q3 2018. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.
- Valeo Financial Advisors held 10,149 shares of GSK worth $532K as of Q2 2026.
- Valeo Financial Advisors bought 532 GSK shares in Q2 2026, an estimated $28.1K.
- GSK made up 0.01% of Valeo Financial Advisors's portfolio in Q2 2026, its #431 holding.
- Valeo Financial Advisors first reported a position in GSK in Q3 2017 and has held it in 36 quarters since.
- Valeo Financial Advisors's GSK position peaked at $1.5M in Q3 2018.
- 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.
Based on Valeo Financial Advisors's 13F filing for Q2 2026, filed 8 Jul 2026.